Physician profile
Rajasree S Roy
NPI 1629173604
$1,976.57
in general payments reported to CMS, 2019-2025
33 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $300 · 2021: $184 · 2022: $18.82 · 2023: $220 · 2024: $254 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $266.55 | 2020-2021 | |
| Seagen INC. | $189.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $184.42 | 2019-2025 | Keytruda, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $172.57 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $124.99 | 2023 | Monoferric |
| Puma Biotechnology, INC. | $120.29 | 2019 | |
| Amgen INC. | $119.09 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $100.76 | 2019 | |
| Menarini Silicon Biosystems, INC. | $72.01 | 2023-2024 | Cellsearch |
| Springworks Therapeutics, INC. | $56.61 | 2024-2025 | Ogsiveo |
| Takeda Pharmaceuticals U.S.A., INC. | $52.87 | 2019-2021 | |
| Eisai INC. | $45.63 | 2023-2024 | |
| Tempus Ai, INC | $45.11 | 2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $30.11 | 2025 | Ojjaara |
| Amag Pharmaceuticals, INC. | $29.29 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $27.16 | 2025 | Monjuvi, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $26.82 | 2024 | |
| Foundation Medicine, INC. | $26.70 | 2023 | Foundationone Cdx |
| Mirati Therapeutics, INC. | $26.41 | 2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.30 | 2025 | |
| Tersera Therapeutics LLC | $25.04 | 2025 | Zoladex |
| Abbott Laboratories | $24.68 | 2024 | Optis |
| Karyopharm Therapeutics INC. | $23.46 | 2023 | Xpovio |
| Genentech USA, INC. | $21.82 | 2025 | Tecentriq, Tecentriq Hybreza |
| Agios Pharmaceuticals, INC. | $20.24 | 2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 | |
| Beone Medicines USA, INC. | $18.84 | 2025 | Brukinsa |
| Ge Healthcare | $18.82 | 2022 | |
| Abbvie INC. | $18.65 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.66 | 2021 | |
| Pharmaessentia USA Corporation | $13.83 | 2025 | Besremi |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajasree Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.